Posted by Michael Wonder on 28 Aug 2024
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
27 August 2024 - Eli Lilly today announced Zepbound (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.
The single-dose vials are priced at a 50% or greater discount compared to the list price of all other incretin medicines for obesity.
